The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Biosynex, NCYT ex-suitor likes to get it's M&A done in Q1. They've recently taken majority shares in three distributors in the Nordics. Previously M&A generally involved R&D or patents businesses and had at least a bit of a French tinge. So looks like their apparent loss of interest in NCYT may have been the result of a change in strategy
https://www.boursorama.com/cours/1rPALBIO/
Some SP action attracts the usual clown show, I'm happy to have a day clawing back some losses. I'd be even happier if the SP found a floor in the 80's as a starting point for a bit of going upwards consistently,
So how much was it it worth? <£1mm is a one off payment for that amount worth an RNS? IIRC there were est. costs of £.5mm (?) associated with closing the businesses, so anything above -£.5mm is good n'est-ce pas
I was wrong back on the 12/12 when I said
"Only two reasons to move the BoD to Southampton. Either
A) Camberley is closing, everyone is being made redundant and the lease getting disposed off.
B) Camberley is staying open and there's another reason to move the BoD to Primer Design."
Turns out the whole thing was disposed off. But there might still be other reasons for moving the BoD
Those who interpreted DA's announcement on Microgen as closing the actual business where closer to the reality than I, who thought it was merely stopping production of products.
But why the griping, it's offices and staff we don't need or nor can afford and products that apparently lost money.
" and i see huge numbers of patients who tell me their LFTs are negative for covid but have flu like illness . I end up telling them to go and get the PCR test done as its more reliable ."
Amazed you're seeing huge numbers of people with flu like illness as NHS advice is not to go unless really ill. If they are really ill why tell them to get a PCR test costing ~£100, why not just treat them
Also why are you always posting during a GPs work hours.
Maybe you should go back to using the Mr Dribbles account. It'll be a lot simpler for you
I guessed that Brent and the 'consultants poring over contracts' bit, it was a general consoling that hopefully it wasn't that bad. But all contracts are pored over it's a contract thing. I suppose the added danger is HMG's 'buyers remorse'
Brent PPE Medpro is very different from NCYT, it was set up overnight and supplying simple stuff badly and expensively and linked to political favours. BUT, not to say they weren't all on the same list, but hoping NCYT was much further down.
Interesting thread, blast from the past, an interesting read, that kid's posting history is impressive they write essays
Handy wouldn't agree with a buyback to canx but a buyback to hold in treasury, I'd be curious to see the outcome. When they finally start to grow again it would (I think) be a kick start to get the SP going. But what do I know apart from I do think there is a need for fresh directors who have done these kind of things before to replace the appointees from blue chips
going going, think she's gone now, Sarah Humphreys Head Of Sales - Clinical, UK & I
https://www.linkedin.com/in/sarah-humphreys-8b617523/
And there goes the Global Director of Marketing.
https://www.linkedin.com/in/darren-tomlinson-b745bb13/
And so departs the EA to CxOs'
https://www.linkedin.com/in/alisonadkinsea/
BoD moved to Southampton, CEO gone, 1 NED gone, EA gone, someone is shaking the tree.
"no viable business" the founders of Primer Design started with £30,000 and raised no more funding, 15 years later they sold it for ~£10mm it's now the main earner for NCYT. Jim Wicks invested some of his money in a new business Youseq, 20-30 employees and doing well.
NCYT is very much a viable business, let's just get this annus horribilis done with ( as Lizzie would say)
Louis, I think his strengths were/are dealmaking, raising finance, doing M&A, Lab21 were very well connected at one time. I'll annoy some people again by pointing out that he did a reverse takeover of NCYT and to have all those skills makes you better than most business people. But integrating people and creating a positive culture and day to day management I'm not so sure considering NCYTs current state.
So yeah PI right place at the right time, piece of cake, just climb to the top of a pharma business and wait.
60/40 for GM to return, all day long, I'm guessing he got the gig earlier this year to manage the business going over a few bumps if he sorted that loan then fair play to him. People are looking at the eyewatering rate and fees but ignore the risk, the terms could have been a lot worse, or indeed no loan at all. I'd 100% have GM back, not as CEO but on the BoD, he has contacts and knowledge that NCYT lacks today.
PI, it's Christmas, not a mouse is stirring in the markets, it doesn't take much to move any SP at the mo up or down. Doubt if rate hikes matter atm either as they are all telegraphed well in advanced. Trading update at the end of Jan will be awful but after that things will happen. Sit tight.